Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
CardiovascularINJECTIONGeneric

PRIMAXIN

CILASTATIN SODIUM; IMIPENEM

Standard Dose
EQ 250MG BASE/VIAL;250MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview PRIMAXIN is listed in Drugs@FDA under application 062756 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient CILASTATIN SODIUM; IMIPENEM Form and strength INJECTABLE;INJECTION - EQ 250MG BASE/VIAL;250MG/VIAL Sponsor MERCK Submission history Latest submission status date: 2017-04-02 00:00:00.

Structured Monograph

Clinical summary

Approval overview PRIMAXIN is listed in Drugs@FDA under application 062756 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CILASTATIN SODIUM; IMIPENEM Form and strength INJECTABLE;INJECTION - EQ 250MG BASE/VIAL;250MG/VIAL Sponsor MERCK Submission history Latest submission status date: 2017-04-02 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.